BioSpace News Archive

- Janssen’s DARZALEX FASPRO™ is a subcutaneous co-formulation of DARZALEX® and Halozyme’s ENHANZE® technology - - Innovative, fixed-dose formulation demonstrates consistent efficacy to intravenous DARZALEX® with lower rate of infusion-related reactions - - Can be administered in three to five minutes compared to multi-hour infusions with intravenous DARZALEX® -

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its strategic process.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the retirement of Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, which was previously planned and disclosed, after a more than 30-year career in biotechnology and pharmaceutical research, development, and sales and marketing.

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after the market close on Monday, May 11, 2020.

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Christine Matthews as the company’s chief financial officer (CFO).

3M announced that it has completed the sale of substantially all of its drug delivery business to an affiliate of Altaris Capital Partners, LLC., for approximately $650 million in total consideration, including cash, an interest-bearing security, and a 17 percent noncontrolling interest in the new company, Kindeva Drug Delivery, that will operate the business.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement and minimally invasive devices for the treatment of refractory angina, today announced that the Nasdaq Hearings Panel has granted the Company’s request for an extension through August 17, 2020

Maxor Specialty, IVSolutions, and Pharmaceutical Specialties, Inc. are now combined under one name--Maxor Specialty Pharmacy

Centene Corporation (NYSE: CNC) announced today it will present in a virtual format at the BofA Securities 2020 Health Care Conference, to be held from May 12-14, 2020 . Centene will present on Wednesday, May 13, 2020 , at 9:40 a.m. Eastern Daylight Time (EDT). A simultaneous live audio webcast is available at: http://www.veracast.com